world
U.S. to supply experimental Ebola drug to Congo for trial
The U.S. will provide an experimental drug for use in a clinical trial in the region. Officials initially limited the drug to American use but later expanded access for the trial.
SemaforAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The U.S. will provide an experimental Ebola drug to Congo for a clinical trial in the region. Officials initially said the MBP134 drug cocktail from California's Mapp Biopharmaceutical would only be used on Americans. The trial could help with eventual U.S. regulatory approval.
Additional trials planned The WHO also said trials for Remdesivir, used to treat COVID-19, would start next week for Ebola patients. Slowing the virus' spread has been hampered by the fact that there is no known treatment or vaccine for the new Bundibugyo strain.
Scientists are racing to develop four vaccines, two of which could be ready for clinical trials in two months, the head of a global vaccine coalition recently told Semafor. Disagreements over pathogen sharing have slowed lab testing to produce new treatments and vaccines, Bloomberg reported.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationLimited · 1 source
